Ambey Laboratories
DHANSA NSE
Ambey Laboratories
ChemicalsNSE: DHANSA Pesticides & Agrochemicals
Key Fundamentals
SMEPesticides & AgrochemicalsChemicalsMarket Cap
₹91.61 Cr
Volatility
High Risk
P/E Ratio
16.6
EBITDA
₹10.92 Cr
Return on Equity
6.26%
Debt to Equity
0.54
Book Value
₹40.09
52W High
₹47
52W Low
₹16.2
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Stock is trading at 0.68 times its book value
Weaknesses
3- Though the company is reporting repeated profits, it is not paying out dividend
- Debtor days have increased from 60.5 to 112 days.
- Working capital days have increased from 64.4 days to 126 days
Growth Rate
Revenue Growth
6.26% lower than
3Y
Net Income Growth
18.54% higher than
3Y
Cash Flow Change
-162% higher than
3Y
ROE
-74.45% lower than
3Y
ROCE
-37.05% higher than
3Y
EBITDA Margin (Avg.)
-11.59% higher than
3Y
Quarterly Results
| Particulars | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|
| Sales | 60 | 68 | 64 | 68 |
| Expenses | 56 | 62 | 60 | 62 |
| Operating Profit | 4 | 6 | 4 | 6 |
| OPM % | 7% | 9% | 6% | 9% |
| Other Income | 1 | 1 | 1 | 0 |
| Interest | 1 | 2 | 1 | 1 |
| Depreciation | 1 | 1 | 2 | 2 |
| PBT | 3 | 4 | 2 | 3 |
| Tax % | 33% | 18% | 25% | 13% |
| Net Profit | 2 | 3 | 2 | 3 |
| EPS in Rs | 0.94 | 1.19 | 0.73 | 1.05 |
Profit & Loss
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|
| Sales | 82 | 85 | 105 | 120 | 131 | 132 |
| Expenses | 72 | 74 | 97 | 111 | 122 | 122 |
| Operating Profit | 10 | 10 | 8 | 9 | 10 | 10 |
| OPM % | 12% | 12% | 7% | 8% | 7% | 7% |
| Other Income | 1 | 1 | 3 | 1 | 2 | 1 |
| Interest | 4 | 3 | 2 | 2 | 3 | 2 |
| Depreciation | 3 | 3 | 3 | 2 | 3 | 4 |
| PBT | 3 | 5 | 6 | 6 | 6 | 5 |
| Tax % | -235% | 26% | 5% | -40% | 21% | — |
| Net Profit | 10 | 4 | 5 | 8 | 5 | 4 |
| EPS in Rs | 211 | 20.11 | 29.52 | 4.13 | 1.92 | 1.78 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|
| Equity Capital | 5 | 18 | 18 | 19 | 25 | 25 |
| Reserves | -13 | 1 | 1 | 13 | 51 | 67 |
| Borrowings | 33 | 18 | 14 | 30 | 41 | 40 |
| Other Liabilities | 20 | 19 | 21 | 18 | 10 | 9 |
| Total Liabilities | 45 | 56 | 54 | 79 | 127 | 140 |
| Fixed Assets | 16 | 25 | 25 | 24 | 23 | 22 |
| CWIP | 1 | 0 | 0 | 4 | 16 | 17 |
| Investments | 0 | 0 | 1 | 1 | 0 | 0 |
| Other Assets | 28 | 31 | 28 | 51 | 88 | 101 |
| Total Assets | 45 | 56 | 54 | 79 | 127 | 140 |
Cash Flow
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Operating | 3 | 6 | 10 | -13 | -34 |
| Investing | -1 | -1 | -4 | -5 | -14 |
| Financing | -1 | -5 | -6 | 18 | 48 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | 2 | 5 | 7 | -18 | -48 |
| CFO/OP | 23 | 47 | 120 | -131 | -347 |
Ratios
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Debtor Days | 31 | 37 | 12 | 57 | 112 |
| Inventory Days | — | — | 78 | 75 | 99 |
| Days Payable | — | — | 74 | 54 | 22 |
| Cash Conversion Cycle | 31 | 37 | 17 | 78 | 189 |
| Working Capital Days | -10 | 11 | 18 | 49 | 126 |
| ROCE % | — | 25% | 22% | 18% | 10% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Ambey Laboratories insights
29 extracted metrics + investor summaries across FY21–FY25.
Documents
1
Analysts/Institutional Investor Meet/Con. Call Updates
11 June 2026 - Q4 FY26 earnings call transcript details ₹30 crore Atrazine capex and ₹240 crore CBG/Biofuel plans. 11 June 2026 - Q4 FY26 earnings call transcript details ₹30 crore Atrazine capex and ₹240 crore CBG/Biofuel plans.
2
Analysts/Institutional Investor Meet/Con. Call Updates
6 June 2026 - Audio recording of 5 June 2026 earnings call for Q4 and FY2025-26 results uploaded. 6 June 2026 - Audio recording of 5 June 2026 earnings call for Q4 and FY2025-26 results uploaded.
3
Investor Presentation
5 June 2026 - FY26 audited results: revenue ₹141.54 crore, EBITDA ₹12.22 crore, PAT ₹5.52 crore; expansion and CBG projects outlined. 5 June 2026 - FY26 audited results: revenue ₹141.54 crore, EBITDA ₹12.22 crore, PAT ₹5.52 crore; expansion and CBG projects outlined.
4
Analysts/Institutional Investor Meet/Con. Call Updates
2 June 2026 - Q4 FY2026 earnings conference call scheduled for 5 June 2026 at 5:00 PM IST. 2 June 2026 - Q4 FY2026 earnings conference call scheduled for 5 June 2026 at 5:00 PM IST.
5
Copy of Newspaper Publication
31 May 2026 - Newspaper advertisement for Q4, half-year and FY2026 standalone/consolidated financial results published on May 31, 2026. 31 May 2026 - Newspaper advertisement for Q4, half-year and FY2026 standalone/consolidated financial results published on May 31, 2026.
Frequently Asked Questions about Ambey Laboratories
What does Ambey Laboratories Ltd do?
Incorporated in 1985, Ambey Laboratories Ltd is in the business of manufacturing and distribution of agro and home hygiene products.[1]
Where is Ambey Laboratories Ltd (AMBEY) listed?
Ambey Laboratories Ltd trades as DHANSA on the NSE.
Which sector does Ambey Laboratories Ltd belong to?
Ambey Laboratories Ltd is classified under the Chemicals sector, in the Pesticides & Agrochemicals industry.
What is the market capitalisation of Ambey Laboratories Ltd?
Ambey Laboratories Ltd has a market capitalisation of ₹91.61 Cr, which places it in the Small Cap band.
What is the PE ratio of Ambey Laboratories Ltd?
Ambey Laboratories Ltd trades at a PE ratio of 16.60, against a book value of ₹40.09 per share.
What is the 52-week high and low of Ambey Laboratories Ltd?
Over the last 52 weeks Ambey Laboratories Ltd has traded between ₹16.2 and ₹47.
What is the Return on Equity (ROE) of Ambey Laboratories Ltd?
Ambey Laboratories Ltd reported a return on equity of 6.26%. Its debt-to-equity ratio is 0.54.
Company Information
Incorporated in 1985, Ambey Laboratories Ltd is in the business of manufacturing and distribution of agro and home hygiene products.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/AMBEY.md for Ambey Laboratories Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.